Hollis-Eden - Worst Pharma Stocks of 2007

Company: Hollis-Eden Pharmaceuticals
Starting stock price: $5.22
Ending stock price: $1.57
Percent Change: -69.92%

Details: On March 7, Hollis-Eden received some really bad news: a highly-anticipated contract with the Department of Health and Human Service was not going to materialize. The agency decided not to buy into Neumune, a therapy for acute radiation syndrome and a prime candidate for stockpiling under the government’s Project BioShield. Hollis-Eden's stock lost a third of its value and not long after, a quarter of the company's staff was laid off. In recent months, however, the company has been mounting a come-back, reporting impressive preclinical data. 

More News:
Hollis-Eden spurs stock price with preclinical news. Report
Hollis-Eden skyrockets on preclinical cancer data. Report
Hollis-Eden to chop work force in restructuring. Report
Hollis-Eden shares plunge on HHS drug rejection. Report

Hollis-Eden - Worst Pharma Stocks of 2007

Suggested Articles

Companies considering this avenue must think through potential implications despite the obvious attraction of early access for patients.

BD says a $1.2 billion investment in its pre-filled syringe business will add surge capacity needed to meet demand in future pandemics.

Ad Environment Matters for Message Receptivity